Research front maps are diagrammatic representations of the core papers
comprising each front. They are selected from the current Research Front set
that are relevant to the featured special topic. The title for this Research
Front Map is "DIPEPTIDYL PEPTIDASE-4 INHIBITION TREATMENT OF TYPE 2
DIABETES," containing
37 core papers. Source dates: 1999-February 28, 2009 (first bimonthly
period 2009).
Each circle represents a highly cited paper whose bibliographic information
is displayed when the user clicks on the circle. The solid lines between circles
represent the strongest co-citation links for each paper (that is, indicating
that the papers are frequently cited together); weaker links are indicated by
dashed lines. Papers close to each other on the map are generally more highly
co-cited. The most recent paper(s) are indicated in pink. Annotations may have
been added to this map which represent the main research themes. These appear as
labels attached to specific regions on the maps.
Note: For best results use the
"landscape orientation" option when printing this page.
Core Papers
Label: Ahren-2002 Title: Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes Journal: DIABETES CARE, 25 (5): 869-875 MAY 2002 Citations: 218 Authors: Ahren, B;Simonsson, E;Larsson, H;Landin-Olsson, M;Torgeirsson, H;Jansson, PA;Sandqvist, M;Bavenholm, P;Efendic, S;Eriksson, JW;Dickinson, S;Holmes, D Addresses:
Lund Univ, Dept Med, B11 BMC, S-22184 Lund, Sweden
Lund Univ, Dept Med, S-22184 Lund, Sweden
Lund Univ, Dept Med, Malmo, Sweden
Univ Gothenburg, Dept Med, Gothenburg, Sweden
Karolinska Hosp, Dept Endocrinol, S-10401 Stockholm, Sweden
Umea Univ, Dept Med, Umea, Sweden
Novartis, Basel, Switzerland
Label: Kim-2005 Title: (2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-alpha]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes Journal: J MED CHEM, 48 (1): 141-151 JAN 13 2005 Citations: 165 Authors: Kim, D;Wang, LP;Beconi, M;Eiermann, GJ;Fisher, MH;He, HB;Hickey, GJ;Kowalchick, JE;Leiting, B;Lyons, K;Marsilio, F;McCann, ME;Patel, RA;Petrov, A;Scapin, G;Patel, SB;Roy, RS;Wu, JK;Wyvratt, MJ;Zhang, BB;Zhu, L;Thornberry, NA;Weber, AE Addresses:
Merck & Co Inc, Merck Res Labs, Mail Code RY800-C206,POB 2000, Rahway, NJ 07065 USA
Merck & Co Inc, Merck Res Labs, Rahway, NJ 07065 USA
Label: Charbonnel-2006 Title: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone Journal: DIABETES CARE, 29 (12): 2638-2643 DEC 2006 Citations: 116 Authors: Charbonnel, B;Karasik, A;Liu, J;Wu, M;Meininger, G;Sitagliptin Study 020 Grp Addresses:
Merck Res Labs, Clin Res, 126 E Lincoln Ave,RY34A-254, Rahway, NJ 07065 USA
Merck Res Labs, Clin Res, Rahway, NJ 07065 USA
Ctr Hosp Univ Nantes, Nantes, France
Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel
Label: Ahren-2005 Title: Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year Journal: DIABETES CARE, 28 (8): 1936-1940 AUG 2005 Citations: 103 Authors: Ahren, B;Pacini, G;Foley, JE;Schweizer, A Addresses:
Lund Univ, Dept Med, B11 BMC, SE-22184 Lund, Sweden
Lund Univ, Dept Med, SE-22184 Lund, Sweden
Italian Natl Res Council, Inst Biomed Engn, Metab Unit, Padua, Italy
Novartis Pharmaceut, E Hanover, NJ USA
Novartis Pharma, Basel, Switzerland
Label: Aschner-2006 Title: Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes Journal: DIABETES CARE, 29 (12): 2632-2637 DEC 2006 Citations: 103 Authors: Aschner, P;Kipnes, MS;Lunceford, JK;Sanchez, M;Mickel, C;Williams-Herman, DE;Sitagliptin Study 021 Grp Addresses:
Merck Res Labs, RY34-A232, Rahway, NJ 07065 USA
Merck Res Labs, Rahway, NJ 07065 USA
Colombian Diabet Assoc, Bogota, Colombia
Diabet & Glandular Dis Res Associates, San Antonio, TX USA
Label: Herman-2005 Title: Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses Journal: CLIN PHARMACOL THER, 78 (6): 675-688 DEC 2005 Citations: 94 Authors: Herman, GA;Stevens, C;Van Dyck, K;Bergman, A;Yi, BM;De Smet, M;Snyder, E;Hilliard, D;Tanen, M;Tanaka, W;Wang, AQ;Zeng, W;Musson, D;Winchell, G;Davies, MJ;Ramael, S;Gottesdiener, KM;Wagner, JA Addresses:
Merck Res Labs, Mail Code RY34-A536,POB 2000, Rahway, NJ 07065 USA
Merck & Co Inc, Whitehouse Stn, NJ USA
SGS Biopharma, Antwerp, Belgium
Label: Raz-2006 Title: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus Journal: DIABETOLOGIA, 49 (11): 2564-2571 NOV 2006 Citations: 93 Authors: Raz, I;Hanefeld, M;Xu, L;Caria, C;Williams-Herman, D;Khatami, H;Sitagliptin Study 023 Grp Addresses:
Merck Res Labs, 126 E Lincoln Ave,RY34-A256, Rahway, NJ 07065 USA
Merck Res Labs, Rahway, NJ 07065 USA
Hadassah Univ Hosp, Ctr Diabet Res, IL-91120 Jerusalem, Israel
Tech Univ Dresden, Ctr Clin Studies, D-8027 Dresden, Germany
Label: Rosenstock-2006 Title: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study Journal: CLIN THER, 28 (10): 1556-1568 OCT 2006 Citations: 90 Authors: Rosenstock, J;Brazg, R;Andryuk, PJ;Lu, KF;Stein, P;Sitagliptin Study 019 Grp Addresses:
Merck Res Labs, 126 E Lincoln Ave,Mail Code RY34-A220, Rahway, NJ 07065 USA
Merck Res Labs, Rahway, NJ 07065 USA
Dallas Diabet & Endocrine Ctr, Dallas, TX USA
Rainier Clin Res Ctr, Renton, WA USA
Label: Weber-2004 Title: Dipeptidyl peptidase IV inhibitors for the treatment of diabetes Journal: J MED CHEM, 47 (17): 4135-4141 AUG 12 2004 Citations: 86 Authors: Weber, AE Addresses:
Merck Res Labs, POB 2000, Rahway, NJ 07065 USA
Merck Res Labs, Rahway, NJ 07065 USA
Label: Nauck-2007 Title: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial Journal: DIABETES OBES METAB, 9 (2): 194-205 MAR 2007 Citations: 76 Authors: Nauck, MA;Meininger, G;Sheng, D;Terranella, L;Stein, PP;Sitagliptin Study 024 Grp Addresses:
Merck Res Labs, 126 E Lincoln Ave,Mail Code RY34-A220, Rahway, NJ 07065 USA
Merck Res Labs, Rahway, NJ 07065 USA
Diabet Zentrum Bad Lauterberg Harz, Bad Lauterberg im Harz, Germany
Label: Rosenstock-2007 Title: Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes - A 24-week, double-blind, randomized trial Journal: DIABETES CARE, 30 (2): 217-223 FEB 2007 Citations: 73 Authors: Rosenstock, J;Mills, D;Baron, MA;Schweizer, A;Dejager, S Addresses:
Dallas Diabet & Endsocrine Ctr Med City, 7777 Forest Ln,C-618, Dallas, TX 75230 USA
Dallas Diabet & Endsocrine Ctr Med City, Dallas, TX 75230 USA
Novartis Pharmaceut, E Hanover, NJ USA
Novartis Pharma AG, Basel, Switzerland
Label: Pratley-2006 Title: Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes Journal: HORMONE METAB RES, 38 (6): 423-428 JUN 2006 Citations: 66 Authors: Pratley, RE;Jauffret-Kamel, S;Galbreath, E;Holmes, D Addresses:
Univ Vermont, Coll Med, Diabet & Metab Translat Med Unit, FAHC Arnold 3412,1 S Prospect St, Burlington, VT 05401 USA
Univ Vermont, Coll Med, Diabet & Metab Translat Med Unit, Burlington, VT 05401 USA
Novartis Pharma AG, Basel, Switzerland
Novartis Pharmaceut, E Hanover, NJ USA
Label: Mu-2006 Title: Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes Journal: DIABETES, 55 (6): 1695-1704 JUN 2006 Citations: 60 Authors: Mu, J;Woods, J;Zhou, YP;Roy, RS;Li, ZH;Zycband, E;Feng, Y;Zhu, L;Li, C;Howard, AD;Moller, DE;Thornberry, NA;Zhang, BB Addresses:
Merck Res Labs, Dept Metab Disorders, RY80W K180,POB 2000, Rahway, NJ 07065 USA
Merck Res Labs, Dept Metab Disorders, Rahway, NJ 07065 USA
Merck Res Labs, Dept Immunol & Inflammat, Rahway, NJ USA
Label: Pi-Sunyer-2007 Title: Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes Journal: DIABETES RES CLIN PRACT, 76 (1): 132-138 APR 2007 Citations: 51 Authors: Pi-Sunyer, FX;Schweizer, A;Mills, D;Dejager, S Addresses:
St Lukes Roosevelt Hosp, Dept Med, 1111 Amsterdam Ave,Room 1020, New York, NY 10025 USA
St Lukes Roosevelt Hosp, Dept Med, New York, NY 10025 USA
Novartis Pharma AG, Basel, Switzerland
Novartis Pharmaceut Corp, E Hanover, NJ USA
Label: Fonseca-2007 Title: Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes Journal: DIABETOLOGIA, 50 (6): 1148-1155 JUN 2007 Citations: 46 Authors: Fonseca, V;Schweizer, A;Albrecht, D;Baron, MA;Chang, I;Dejager, S Addresses:
Tulane Univ, Hlth Sci Ctr, Dept Endocrinol, 1430 Tulane Ave,SL53, New Orleans, LA 70112 USA
Tulane Univ, Hlth Sci Ctr, Dept Endocrinol, New Orleans, LA 70112 USA
Novartis Pharma AG, Basel, Switzerland
Novartis Pharmaceut Corp, E Hanover, NJ USA
Label: Scott-2007 Title: Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes Journal: INT J CLIN PRACT, 61 (1): 171-180 JAN 2007 Citations: 42 Authors: Scott, R;Wu, M;Sanchez, M;Stein, P Addresses:
Merck Res Labs, 126 E Lincoln Ave,RY34-A220, Rahway, NJ 07065 USA
Merck Res Labs, Rahway, NJ 07065 USA
Christchurch Sch Med, Christchurch, New Zealand
Label: Garber-2007 Title: Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study Journal: DIABETES OBES METAB, 9 (2): 166-174 MAR 2007 Citations: 36 Authors: Garber, AJ;Schweizer, A;Baron, MA;Rochotte, E;Dejager, S Addresses:
Baylor Coll Med, Div Endocrinol, 6550 Fannin St,Suite 1045, Houston, TX 77030 USA
Baylor Coll Med, Div Endocrinol, Houston, TX 77030 USA
Novartis Pharma AG, Basel, Switzerland
Novartis Pharmaceut Corp, E Hanover, NJ USA
Label: Goldstein-2007 Title: Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes Journal: DIABETES CARE, 30 (8): 1979-1987 AUG 2007 Citations: 36 Authors: Goldstein, BJ;Feinglos, MN;Lunceford, JK;Johnson, J;Williams-Herman, DE;Sitagliptin 036 Study Grp Addresses:
Merck Res Labs, RY37-A232, Rahway, NJ 07065 USA
Merck Res Labs, Rahway, NJ 07065 USA
Jefferson Med Coll, Div Endocrinol Diabet & Metab Dis, Philadelphia, PA USA
Duke Univ, Ctr Med, Div Endocrinol Metab & Nutr, Durham, NC USA
Label: Hermansen-2007 Title: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin Journal: DIABETES OBES METAB, 9 (5): 733-745 SEP 2007 Citations: 31 Authors: Hermansen, K;Kipnes, M;Luo, E;Fanurik, D;Khatami, H;Stein, P;Sitagliptin Study 035 Grp Addresses:
Merck Res Labs, 126 E Lincoln Ave,Mail Cde Ry34-A256, Rahway, NJ 07065 USA
Merck Res Labs, Rahway, NJ 07065 USA
Aarhus Univ Hosp, DK-8000 Aarhus, Denmark
Diabetes & Glandular Labs, San Antonio, TX USA
Label: Vella-2007 Title: Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes Journal: DIABETES, 56 (5): 1475-1480 MAY 2007 Citations: 30 Authors: Vella, A;Bock, G;Giesler, PD;Burton, DB;Serra, DB;Saylan, ML;Dunning, BE;Foley, JE;Rizza, RA;Camilleri, M Addresses:
Mayo Clin, Coll Med, Endocrine Res Unit, Div Endocrinol Diabet Metab & Nutr, 5 Jo 194,200 1st St SW, Rochester, MN 55905 USA
Mayo Clin, Coll Med, Endocrine Res Unit, Div Endocrinol Diabet Metab & Nutr, Rochester, MN 55905 USA
Mayo Clin, Coll Med, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA
Novartis Pharmaceut, E Hanover, NJ USA
PharmaWrite, Princeton, NJ USA
Label: Brazg-2007 Title: Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes Journal: DIABETES OBES METAB, 9 (2): 186-193 MAR 2007 Citations: 28 Authors: Brazg, R;Xu, L;Dalla Man, C;Cobelli, C;Thomas, K;Stein, PP Addresses:
Merck Res Labs, 126 E Lincoln Ave,RY34-A220, Rahway, NJ 07065 USA
Merck Res Labs, Rahway, NJ 07065 USA
Rainier Clin Res Ctr, Renton, WA USA
Univ Padua, Dept Informat Engn, Padua, Italy
Label: Rosenstock-2008 Title: Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance Journal: DIABETES CARE, 31 (1): 30-35 JAN 2008 Citations: 10 Authors: Rosenstock, J;Holst, JJ;Foley, JE;Deacon, CF;Rendell, M;Rochotte, E;Landin-Olsson, M;Baron, MA Addresses:
Nova Pharmaceut Corp, 1 Hlth Pl, E Hanover, NJ 07936 USA
Nova Pharmaceut Corp, E Hanover, NJ 07936 USA
Dallas Diabet & Endocrine Ctr, Dallas, TX USA
Creighton Diabet Ctr, Omaha, NE USA
Univ Hosp, Lund, Sweden
Univ Copenhagen, Panum Inst, Copenhagen, Denmark
Novarti Pharma AG, Basel, Switzerland
Label: Bolli-2008 Title: Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study Journal: DIABETES OBES METAB, 10 (1): 82-90 JAN 2008 Citations: 9 Authors: Bolli, G;Dotta, F;Rochotte, E;Cohen, SE Addresses:
Nova Pharmaceut Corp, 400 Technol Square, Cambridge, MA 02139 USA
Univ Perugia, Sect Internal Med Endocrinol & Metabol, Perugia, Italy
Univ Studi Siena, Policlin Le Scotte, Siena, Italy
Novartis Pharma AG, Clin Dev, Basel, Switzerland
Nova Pharmaceut Corp, Clin Dev, Cambridge, MA 02139 USA
Label: Utzschneider-2008 Title: The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose Journal: DIABETES CARE, 31 (1): 108-113 JAN 2008 Citations: 7 Authors: Utzschneider, KM;Tong, J;Montgomery, B;Udayasankar, J;Gerchman, F;Marcovina, SM;Watson, CE;Ligueros-Saylan, MA;Foley, JE;Holst, JJ;Deacon, CF;Kahn, SE Addresses:
VA Puget Sound Hlth Care Syst, 1660 S Columbian Wy, Seattle, WA 98108 USA
VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA
Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA
Univ Washington, NW Lipid Metab & Diabet Res Labs, Seattle, WA 98195 USA
Novartis Inst Biomed Res, Cambridge, MA USA
Novartis Pharmaceut, E Hanover, NJ USA
Univ Copenhagen, Panum Inst, Dept Biomed Sci, DK-2200 Copenhagen, Denmark